Junshi Biosciences Shareholders Approve H-Share Buyback MandateTip Ranks·Jul 27 at 06:09 AM01877+0.22%688180+2.15%
Junshi Biosciences Completes RMB300 Million Technology Innovation Bond IssuanceTip Ranks·Jul 22 at 08:08 AM01877+0.22%688180+2.15%
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLCUnusual Whales·Jul 21 at 06:12 PM01877+0.22%688180+2.15%
Junshi Biosciences Wins NMPA Nod to Expand Toripalimab Use in Early-Stage Lung CancerTip Ranks·Jul 21 at 09:09 AM01877+0.22%688180+2.15%
Shanghai Junshi says China regulator accepts label expansion filing for toripalimab chemo in resectable stage II-III NSCLCPUBT·Jul 21 at 08:23 AM01877+0.22%688180+2.15%
BeOne Medicines CEO John Oyler reports disposal of shares worth $75.72 millionPUBT·Jul 17 at 04:31 PM06160-1.07%BGNE0.00%
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell CarcinomaUnusual Whales·Jul 17 at 07:27 AM688506-2.93%02615
Macquarie Raises BEONE MEDICINES TP to HKD257, Reiterates Outperform RatingAASTOCKS News·Jul 13 at 03:20 AMONC-1.88%06160-1.07%
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline ProgressTip Ranks·Jul 12 at 07:25 PM06160-1.07%688235-0.95%
Transthera wins China NMPA clearance for Phase II TT-00973 combo trial in EGFR-mutant NSCLCPUBT·Jul 10 at 09:18 AM688578-3.77%
Junshi Biosciences Calls EGM to Seek Mandate for H-Share BuybackTip Ranks·Jul 8 at 09:38 AM688180+2.15%01877+0.22%
Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)Tip Ranks·Jul 7 at 12:15 AMONC-1.88%BGNE0.00%
Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)GlobeNewswire·Jul 1 at 07:43 PM688180+2.15%01877+0.22%
Junshi Biosciences licenses JS005 rights in Greater China to Fosun Wanbang for CNY 215 million upfrontPUBT·Jul 1 at 06:28 AM688180+2.15%01877+0.22%
